Original ArticleHow to Protect Doxorubicin-Induced Cardiomyopathy in Male Albino Rats?Shaker, Olfat MD*; Sourour, Doaa A MD†Author Information From the *Departments of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University; and †Medical Research and Radiation, Nuclear Materials Authority, Cairo University, Cairo, Egypt. Received for publication November 7, 2009; accepted December 10, 2009. All authors listed have contributed to the work, all authors have agreed to submit the manuscript for publication, and all animal studies have been reviewed by the appropriate ethics committees. The authors report no conflicts of interest. Reprints: Olfat G. Shaker, MD, Faculty of Medicine, Department of Medical Biochemistry and Molecular Biology, Nuclear Materials Authority, Cairo University, Cairo, Egypt (e-mail: [email protected]). Journal of Cardiovascular Pharmacology: March 2010 - Volume 55 - Issue 3 - p 262-268 doi: 10.1097/FJC.0b013e3181cf91ac Buy Metrics Abstract The present study was designed to compare the cardioprotective effects of the combination of lisinopril with growth hormone over lisinopril alone in doxorubicin (Dox)-induced cardiomyopathy in rats. Forty male Wister albino rats were divided into 4 groups: group 1, control group; group 2, received Dox; group 3, received lisinopril + Dox; and group 4, received lisinopril + Dox + growth hormone. Dox (cumulative dose) was administered to rats in 6 equal intraperitoneal injections over a period of 2 weeks. Histopathological changes and plasma aspartate aminotransferase, lactate dehydrogenase, and creatine kinase and plasma levels of matrix metalloproteinase (MMP)-2, tissue inhibitor matrix metalloproteinase (TIMP)-1, and cardiac inducible nitric oxide synthase (iNOS) messenger RNA (mRNA) expression were determined 9 weeks after the first dose of Dox. Dox produced cardiac structural injury and significant elevation in plasma levels of cardiac enzymes, MMP-2, and cardiac iNOS mRNA expression together with significant reduction in plasma TIMP-1 level. Lisinopril significantly decreases plasma MMP-2 level and cardiac iNOS mRNA expression by 13% and 15%, respectively, in group 3 compared with 36% and 47%, respectively, in group 4 as compared with group 2. In addition, compared with Dox group, lisinopril significantly increases plasma TIMP-1 level by 23% compared with 49% in group 4. We can conclude that the combination of lisinopril and growth hormone produced better cardioprotective effect against Dox-induced cardiomyopathy. This effect may be attributed on their antiremodeling actions by regulating plasma MMP-2/TIMP-1 levels and to the reduction of cardiac iNOS mRNA expression. © 2010 Lippincott Williams & Wilkins, Inc.